Last reviewed · How we verify
Hepatitis A & B vaccine
At a glance
| Generic name | Hepatitis A & B vaccine |
|---|---|
| Also known as | Twinrix, Engerix-B |
| Sponsor | University of California, San Francisco |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection (PHASE1, PHASE2)
- The COMBAT HBV Feasibility Trial (PHASE4)
- Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults (PHASE1)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies (PHASE3)
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (PHASE2)
- Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hepatitis A & B vaccine CI brief — competitive landscape report
- Hepatitis A & B vaccine updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI